STOCK TITAN

Manhattan Bridge Capital, Inc 8-K Filings

LOAN NASDAQ

Every 8-K that Manhattan Bridge Capital, Inc (LOAN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 8-K covers material events a company has to report between its quarterly reports, so if you follow LOAN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LOAN filings page.

Rhea-AI Summary

Manhattan Bridge Capital, Inc. reported the results of its 2026 Annual Meeting of Shareholders held on June 18, 2026. Shareholders elected six directors, with support ranging from 4,831,640 to 4,890,307 votes in favor for each nominee and 3,339,438 broker non-votes recorded.

Shareholders also gave advisory approval to appoint Hoberman & Lesser, LLP as independent auditors for the fiscal year ending December 31, 2026, with 8,255,336 votes for, 79,715 against, and 103,252 abstentions.

Rhea-AI Summary

Manhattan Bridge Capital, Inc. entered into an amendment to its Amended and Restated Credit and Security Agreement. The amendment extends the term of the credit facility through March 31, 2026, keeping the company’s revolving line of credit in place for a longer period.

The changes also reflect the departure of Mizrahi Tefahot Bank Ltd. as a lender and a reallocation of commitments among the remaining lenders. In connection with this, the company issued a Second Amended and Restated Revolving Credit Note in favor of Webster Bank, increasing the note’s original principal amount from $15,000,000 to $22,500,000. The detailed terms are set out in the amendment and the new Webster note attached as exhibits.

Rhea-AI Summary

Manhattan Bridge Capital, Inc., through its wholly owned subsidiary MBC Funding II Corp., entered into a new revolving credit facility with Valley National Bank for up to $10,000,000. The line of credit is secured by an all-assets security agreement and is supported by guarantees from the company and from Assaf Ran, whose personal liability is capped at $500,000.

Borrowings under the note mature on the earlier of December 12, 2027 or an event of default and bear interest at a floating rate equal to Term SOFR, with a 3.00% floor, plus 2.95% per year. MBC Funding II will also pay a 0.20% upfront fee on the total commitment and a 0.25% annual fee on the average unused portion of the facility. The agreement includes customary covenants, reporting requirements and events of default.

Separately, MBC Funding II completed the redemption of all $6,000,000 principal amount of its 6.00% Senior Secured Notes due April 22, 2026 at 100% of principal plus accrued and unpaid interest on December 15, 2025, and no such notes remain outstanding. The company also entered into Amendment No. 8 to its existing credit and security agreement to permit the new facility and related guarantees.

Rhea-AI Summary

Manhattan Bridge Capital, Inc. and its subsidiary MBC Funding II Corp. announced a full redemption of MBC Funding II’s 6.00% Senior Secured Notes due April 22, 2026. These Notes, originally issued with an aggregate principal amount of $6,000,000 and trading on NYSE American under the symbol LOAN/26, carry interest at 6.00% per year, paid monthly on the 15th of each month.

All outstanding Notes are scheduled to be redeemed on December 15, 2025 at a price equal to 100% of the outstanding principal plus accrued and unpaid interest up to, but excluding, the redemption date. After this redemption is completed, no Notes will remain outstanding and they will be removed from listing on NYSE American.

Rhea-AI Summary

Manhattan Bridge Capital, Inc. announced that its Board of Directors has authorized a share buyback program allowing the company to repurchase up to 100,000 shares of its common stock. The company may carry out these repurchases through open market purchases, privately negotiated transactions or other methods, providing flexibility in how the program is executed. The authorization runs for 12 months and does not require the company to buy any specific number of shares, and the Board may terminate, increase or decrease the program at its discretion.